Translational precision medicine: an industry perspective

Journal of Translational Medicine

Sohail Ahmed¹  Richard Siegel²  Martin Fink²  Dominik Hartl²  Scott Kennedy²  Enrico Ferrero²  Markus Hinder²  Jason Laramie²  Valeria de Luca²  Anna Kostikova²  John Millholland³  Alexander Schuhmacher⁴  Luca Piali⁵  Adrian Roth⁵ 

[1] ;Novartis Institutes for BioMedical Research;Novartis Precision Medicine;Reutlingen University;Roche Innovation Center Basel;

关键词: Translational medicine;    Precision medicine;    Drug development;    Biomarkers;    Multi-omics;    Modeling;   

DOI  :  10.1186/s12967-021-02910-6

来源: DOAJ

【 摘 要 】

Abstract In the era of precision medicine, digital technologies and artificial intelligence, drug discovery and development face unprecedented opportunities for product and business model innovation, fundamentally changing the traditional approach of how drugs are discovered, developed and marketed. Critical to this transformation is the adoption of new technologies in the drug development process, catalyzing the transition from serendipity-driven to data-driven medicine. This paradigm shift comes with a need for both translation and precision, leading to a modern Translational Precision Medicine approach to drug discovery and development. Key components of Translational Precision Medicine are multi-omics profiling, digital biomarkers, model-based data integration, artificial intelligence, biomarker-guided trial designs and patient-centric companion diagnostics. In this review, we summarize and critically discuss the potential and challenges of Translational Precision Medicine from a cross-industry perspective.

【 授权许可】

Unknown